Jung G L, Anderson P C, Bailey M, Baillet M, Bantle G W, Berthiaume S, Lavallée P, Llinas-Brunet M, Thavonekham B, Thibeault D, Simoneau B
Bio-Méga Research Division, Boehringer Ingelheim (Canada) Ltd, Laval, Québec.
Bioorg Med Chem. 1998 Dec;6(12):2317-36. doi: 10.1016/s0968-0896(98)80011-4.
Renin inhibitors containing a 4,5- or a 3,5-dihydroxy-2-substituted-6-phenylhexanamide fragment at the P2-P3 sites have been prepared and evaluated. The four possible diastereomeric diols of the two series of inhibitors were synthesized to determine the optimal configuration of the carbinol centers for these replacements. The most potent inhibitors of each series, la and 2c have a molecular weight of only 503 and IC50 values of 23 and 20 nM in a human plasma renin assay at pH 6.0. Their very low aqueous solubility limited their further evaluation. The efficacy of these P2-P3 replacements is a result of their ability to maintain the important hydrogen-bonds with the enzyme. Due to conformational differences with the dipeptide, adjustment at the P2 side chain was required. These 4,5- and 3,5-dihydroxyhexanamide segments could be seen as novel N-terminal dipeptide replacements.
